Get bonus pills when buying Cardizem ONLINE

M2 PRESSWIRE-28 January 2003-US ATTORNEY GENERAL MARYLAND: Curran announces USD80m settlement with makers of popular heart medication - Cardizem(C)1994-2003 M2 COMMUNICATIONS LTD RDATE:01272003 Attorney …

WASHINGTON, Aug. 13 /U.S. Newswire/ — Hypertension patients and
others who took the medication Cardizem(r) CD or its generic
equivalents between 1998-2003 may be entitled to money from a $21
million fund …

Canada’s Biovail has achieved a significant milestone with the US approval of Cardizem LA (diltiazem), the first drug developed under a New Drug Application that the company will launch directly to physicians. Cardizem LA is a graded-release formulation of the calcium channel blocker that provides 24-hour control of blood…

Teva will launch Diltiazem Extended Release Capsules (once-a-day) in all dosage strengths. Diltiazem ER is the generic equivalent of Aventis’ (formerly Hoechst) Cardizem CD, which is indicated for the treatment of hypertension and angina. Sales of Cardizem CD in the. United States for the 12 months ended June 30 exceeded $650 million, Teva said.

Related Results

Cardize…

Biovail Corp. has purchased the rights to market the Cardizem line of calcium channel blockers in North America from Aventis. Biovail will pay Aventis $409.5 million. Aventis will continue to manufacture the Cardizem line.
The Cardizem product line includes Cardizem CD (diltiazem) for hypertension…

WHEN THE CONDUCT OF HEALTH CARE PROVIDERS IS SO OUTRAGEOUS AND CLEARLY CONTRARY TO APPLICABLE STANDARDS OF CARE, PUNITIVE DAMAGES CAN BE AWARDED. Often, there is a direct correlation between the amount of punitive damages awarded and the extent to which the conduct is outrageous and violative of applicable standards of care. That was the situation in this unusual case in whic…

Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–March 3, 2004
Biovail Corporation (NYSE:BVF) (TSX:BVF):
— Core Product sales revenue increases by 59%
— Core Product Revenue $172 million for 2003 versus $108 million
for 2002
— Biovail Pharmaceuticals Canada Product Revenue $85 million for
2003 versus $33 million for 2002
— Wellbutrin XL Revenue $65 million for 2003
…

FORT LAUDERDALE, Fla. — Andrx Corporation (Nasdaq:ADRX) (”Andrx” or “Company”) today announced that it has a pending abbreviated new drug application (”ANDA”) with the United States Food and Drug Administration (”FDA”) for generic versions of Cardizem(R) LA (diltiazem HCl extended-release tablets), 120mg, 180mg, 240mg, 300mg, 360mg and 420mg strengths. Andrx initially filed its ANDA for the 420mg s…

Business Editors/Health & Medical Writers
FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–March 12, 2001
Andrx Corporation — Andrx Group (Nasdaq:ADRX) today announced that Health Canada, the Canadian health authority, has approved the sale throughout Canada of all four strengths of its bioequivalent version of Cardizem(R) CD. Licensed to Rhoxalpharma, Inc., this product, marketed as Rhoxal-diltiazem CD, has already been launched. Diltiazem CD remains one of the largest selling pharmaceuticals i…

M2 PRESSWIRE-3 April 2007-Biotech News: In- Depth Research on Biovail Corp(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:03042007 In- Depth Research on Biovail Corp (NYSE:BVF) Biovail Corporation engages in the formulation, clinical testing, registration, manufacture, and commercializat…